Literature DB >> 7654797

Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update.

M Petri.   

Abstract

OBJECTIVE: To determine the frequency of musculoskeletal system damage among patients in the Hopkins Lupus Cohort, over time, and to determine predictors of musculoskeletal damage (including avascular necrosis of bone, osteoporosis, and fracture) in the same cohort.
METHODS: Evaluation of the cohort visit database (from 1989 or at the time of entry into the cohort if later than 1989) for the 407 patients with systemic lupus erythematosus (SLE). Musculoskeletal damage was measured by the SLICC/ACR Damage Index.
RESULTS: Total damage and musculoskeletal damage accumulated from the time of diagnosis of SLE, and musculoskeletal damage continued over time, with avascular necrosis of bone being the most common form. African-Americans and SLE patients of lower socioeconomic status were more likely to experience musculoskeletal damage. Use of corticosteroids was a major risk factor for both avascular necrosis of bone and osteoporosis.
CONCLUSION: Musculoskeletal damage remains one of the major sequela of SLE. Reduction of the modifiable risk factors (especially prednisone dose) is the key to both primary and secondary prevention efforts.

Entities:  

Mesh:

Year:  1995        PMID: 7654797     DOI: 10.1002/art.1790080305

Source DB:  PubMed          Journal:  Arthritis Care Res        ISSN: 0893-7524


  29 in total

Review 1.  Non-pharmacologic therapies for systemic lupus erythematosus.

Authors:  M Fangtham; S Kasturi; R R Bannuru; J L Nash; C Wang
Journal:  Lupus       Date:  2019-04-08       Impact factor: 2.911

Review 2.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

Review 3.  Inflammatory diseases and bone fragility.

Authors:  K Briot; P Geusens; I Em Bultink; W F Lems; C Roux
Journal:  Osteoporos Int       Date:  2017-09-15       Impact factor: 4.507

Review 4.  Th17, gut, and HIV: therapeutic implications.

Authors:  Peter W Hunt
Journal:  Curr Opin HIV AIDS       Date:  2010-03       Impact factor: 4.283

5.  Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling.

Authors:  Yu Tang; Hao Xie; Jinyun Chen; Linyu Geng; Haifeng Chen; Xia Li; Yayi Hou; Liwei Lu; Songtao Shi; Xiaofeng Zeng; Lingyun Sun
Journal:  Stem Cells Dev       Date:  2012-10-10       Impact factor: 3.272

6.  Development of Biomarker Models to Predict Outcomes in Lupus Nephritis.

Authors:  Bethany J Wolf; John C Spainhour; John M Arthur; Michael G Janech; Michelle Petri; Jim C Oates
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

Review 7.  Does vasculitis alone cause AVN? A review of literature.

Authors:  Rtika R Abraham; John O Meyerhoff
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

Review 8.  Bone health in systemic lupus erythematosus.

Authors:  Pantelis Panopalis; Jinoos Yazdany
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

Review 9.  Current Perspectives on Arthroplasty in Systemic Lupus Erythematosus: Rates, Outcomes, and Adverse Events.

Authors:  Shanthini Kasturi; Susan Goodman
Journal:  Curr Rheumatol Rep       Date:  2016-09       Impact factor: 4.592

10.  Urinary excretion of the pyridinium cross-links of collagen in systemic lupus erythematosus.

Authors:  Y Kipen; R Will; B J Strauss; E F Morand
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.